Last reviewed · How we verify
Fentanyl matrix
At a glance
| Generic name | Fentanyl matrix |
|---|---|
| Sponsor | Janssen Korea, Ltd., Korea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Minimal Flow Anesthesia and Infection Risk (NA)
- Morphine or Fentanyl for Refractory Dyspnea in COPD (PHASE4)
- Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain (PHASE4)
- Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain
- Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip
- The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement
- Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study
- Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fentanyl matrix CI brief — competitive landscape report
- Fentanyl matrix updates RSS · CI watch RSS
- Janssen Korea, Ltd., Korea portfolio CI